Ginos Matthew A, Page Grier P, Michalowicz Bryan S, Patel Ketan J, Volker Sonja E, Pambuccian Stefan E, Ondrey Frank G, Adams George L, Gaffney Patrick M
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA.
Cancer Res. 2004 Jan 1;64(1):55-63. doi: 10.1158/0008-5472.can-03-2144.
Molecular studies of squamous cell carcinoma of the head and neck (HNSCC) have demonstrated multiple genetic abnormalities such as activation of various oncogenes (Ras, Myc, epidermal growth factor receptor, and cyclin D1), tumor suppressor gene inactivation (TP53 and p16), and loss of heterozygosity at numerous chromosomal locations. Despite these observations, accurate and reliable biomarkers that predict patients at highest risk for local recurrence have yet to be defined. In an effort to identify gene expression signatures that may serve as biomarkers, we studied 41 squamous cell carcinoma tumors (25 primary and 16 locally recurrent) from various anatomical sites and 13 normal oral mucosal biopsy samples from healthy volunteers with microarray analysis using Affymetrix U133A GeneChip arrays. Differentially expressed genes were identified by calculating generalized t tests (P < 0.001) and applying a series of filtering criteria to yield a highly discriminant list of 2890 genes. Hierarchical clustering and image generation using standard software were used to visualize gene expression signatures. Several gene expression signatures were readily identifiable in the HNSCC tumors, including signatures associated with proliferation, extracellular matrix production, cytokine/chemokine expression, and immune response. Of particular interest was the association of a gene expression signature enriched for genes involved in tumor invasion and metastasis with patients experiencing locally recurrent disease. Notably, these tumors also demonstrated a marked absence of an immune response signature suggesting that modulation of tumor-specific immune responses may play a role in local treatment failure. These data provide evidence for a new gene expression-based biomarker of local treatment failure in HNSCC.
头颈部鳞状细胞癌(HNSCC)的分子研究已证实存在多种基因异常,如各种癌基因(Ras、Myc、表皮生长因子受体和细胞周期蛋白D1)的激活、肿瘤抑制基因失活(TP53和p16)以及多个染色体位点的杂合性缺失。尽管有这些发现,但尚未确定能预测局部复发风险最高患者的准确可靠生物标志物。为了识别可能作为生物标志物的基因表达特征,我们使用Affymetrix U133A基因芯片阵列,通过微阵列分析研究了来自不同解剖部位的41例鳞状细胞癌肿瘤(25例原发性和16例局部复发性)以及13例来自健康志愿者的正常口腔黏膜活检样本。通过计算广义t检验(P < 0.001)并应用一系列筛选标准来鉴定差异表达基因,从而得出一份由2890个基因组成的高度判别性列表。使用标准软件进行层次聚类和图像生成,以可视化基因表达特征。在HNSCC肿瘤中很容易识别出几种基因表达特征,包括与增殖、细胞外基质产生、细胞因子/趋化因子表达和免疫反应相关的特征。特别令人感兴趣的是,一种富含参与肿瘤侵袭和转移基因的基因表达特征与局部复发性疾病患者之间的关联。值得注意的是,这些肿瘤还明显缺乏免疫反应特征,这表明肿瘤特异性免疫反应的调节可能在局部治疗失败中起作用。这些数据为HNSCC局部治疗失败的一种基于新基因表达的生物标志物提供了证据。